Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement
May 03, 2023 07:00 ET
|
Magenta Therapeutics
Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus’ portfolio of next-generation antibody complement therapeutics Combined company is expected to have...
Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan
March 31, 2023 16:10 ET
|
Magenta Therapeutics
CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously...
Magenta Therapeutics to Explore Strategic Alternatives
February 02, 2023 16:05 ET
|
Magenta Therapeutics
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company focused on improving stem cell transplantation, today announced that...
Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety
January 25, 2023 16:05 ET
|
Magenta Therapeutics
CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA) today announced that the latest participant dosed at the Cohort 3 level (0.08 mg/kg) in the ongoing MGTA-117...
Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial
December 20, 2022 09:00 ET
|
Magenta Therapeutics
– Cohort 4 Dosing Stopped per Clinical Trial Protocol due to Dose-Limiting Toxicities – – Plan to Dose Additional Participants in Cohort 3 per Clinical Trial Protocol – CAMBRIDGE, Mass., Dec. 20,...
Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates
December 12, 2022 16:30 ET
|
Magenta Therapeutics
– MGTA-117 preliminary clinical results from 15 patients across three dose-escalation cohorts of the ongoing Phase 1/2 clinical trial shows single-agent activity with no dose-limiting toxicities;...
Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial
December 12, 2022 08:00 ET
|
Magenta Therapeutics
CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of...
Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights
November 03, 2022 09:01 ET
|
Magenta Therapeutics
– New clinical results from ongoing MGTA-117 Phase 1/2 clinical trial support earlier observations of target binding, target cell depletion, rapid drug clearance and a favorable tolerability profile;...
Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting
November 03, 2022 09:01 ET
|
Magenta Therapeutics
– Oral presentation of MGTA-117 Phase 1/2 dose escalation clinical trial abstract, with additional clinical data supporting proof-of-mechanism – – Poster presentation of data from a MGTA-117...
Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference
November 01, 2022 08:00 ET
|
Magenta Therapeutics
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of...